Download PDFPDF

A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Letter to the editor regarding published article by de Groot et al. ‘A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands’
    • Lisa Aniek de Jong, PhD candidate pharmacoeconomics Unit of PharmacoTherapy, -Epidemiology & -Economics, University of Groningen, the Netherlands
    • Other Contributors:
      • Lotte Westerink, PhD candidate pharmacoeconomics
      • Evgeni Dvortsin, Health economist
      • Maarten Postma, Professor in pharmacoeconomics

    Dear editor,

    We would like to congratulate de Groot et al. for having performed this cost of illness study regarding hypoglycaemic events in insulin-treated diabetic patients in the Netherlands, which is a great step forward to a broader perspective on the hypoglycaemic burden specifically for the Netherlands [1]. In this study, Groot et al. use data from self-assessment questionnaires in type 1 (T1DM) and type 2 diabetes mellitus (T2DM) patients in the Netherlands during a 4-week follow up period, to assess the costs of hypoglycaemic events. The article sheds light on the substantial impact which direct and indirect costs related to hypoglycaemia have on the total economic burden of diabetes. Accordingly, the study suggests that preventing hypoglycaemia can lead to an increase in quality of life, but also lead to a reduction in DM-related health care costs. We would like to elaborate on the results of this study to stimulate debate, and encourage further research.

    Using self-reported data on hypoglycaemic events due to insulin treatment, de Groot et al. estimated that the total annual costs of hypoglycaemia, lies between a range of €112.5 million to €590.8 million in the Netherlands. Further research could support the conclusions reached in this study, for example, using alternative sources and methods to estimate costs. In addition, further research could be conducted on the incidence and frequency of hypoglycaemia and its potential consequences. To furthe...

    Show More
    Conflict of Interest:
    None declared.